GRANULES:NSE-Granules India Limited (INR)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSE

Last Closing Price

INR 254.00

Change

-26.45 (-9.43)%

Market Cap

INR 70.43B

Volume

1.55M

Avg Analyst Target

INR 362.50 (+42.72%)

Avg User Target

INR
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Granules India Limited (GRANULES) Stock Analysis:
Based on the Granules India Limited stock forecasts from 2 analysts, the average analyst target price for Granules India Limited is INR 362.50 over the next 12 months. Granules India Limited’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Granules India Limited is Slightly Bullish , which is based on 6 positive signals and 3 negative signals. At the last closing, Granules India Limited’s stock price was INR 254.00. Granules India Limited’s stock price has changed by -3.46% over the past week, -11.37% over the past month and -20.48% over the last year.

About

Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs) in India, North America, Europe, Latin America, and internationally. The company's APIs in various therapeutic categories i ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-25 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
SUNPHARMA:NSE Sun Pharmaceutical Industries ..

+1.30 (+0.14%)

INR2,206.30B 34.35 21.22
DIVISLAB:NSE Divi's Laboratories Limited

-142.35 (-3.89%)

INR989.52B 38.54 31.87
DRREDDY:NSE Dr. Reddy's Laboratories Limit..

-39.65 (-0.91%)

INR722.62B 30.73 14.28
TORNTPHARM:NSE Torrent Pharmaceuticals Limite..

+45.60 (+1.76%)

INR440.13B 36.09 18.30
PEL:NSE Piramal Enterprises Limited

+2.70 (+0.15%)

INR422.84B 34.11 11.89
ALKEM:NSE Alkem Laboratories Limited

+37.00 (+1.26%)

INR354.25B 21.53 15.90
AUROPHARMA:NSE Aurobindo Pharma Limited

-15.45 (-2.87%)

INR319.92B 11.16 6.57
LAURUSLABS:NSE Laurus Labs Limited

-14.10 (-2.49%)

INR305.97B 37.09 22.65
LUPIN:NSE Lupin Limited

-10.60 (-1.76%)

INR279.20B 25.10 71.88
IPCALAB:NSE IPCA Laboratories Limited

-17.60 (-1.84%)

INR246.36B 26.92 17.53

ETFs Containing GRANULES

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -24.45% 44% F 26% F
Dividend Return 0.07% 44% F 2% F
Total Return -24.38% 45% F 26% F
Trailing 12 Months  
Capital Gain -20.34% 42% F 18% F
Dividend Return 0.39% 31% F 22% F
Total Return -19.95% 44% F 18% F
Trailing 5 Years  
Capital Gain 86.42% 71% C- 74% C
Dividend Return 3.67% 65% D 50% F
Total Return 90.09% 73% C 74% C
Average Annual (5 Year Horizon)  
Capital Gain 45.38% 78% C+ 80% B-
Dividend Return 0.68% 69% D+ 50% F
Total Return 46.06% 77% C+ 81% B-
Risk Return Profile  
Volatility (Standard Deviation) 83.26% 28% F 27% F
Risk Adjusted Return 55.32% 67% D+ 79% C+
Market Capitalization 70.43B 75% C 79% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 17.11 65% D 56% F
Price/Book Ratio 2.58 57% F 42% F
Price / Cash Flow Ratio 21.21 47% F 29% F
EV/EBITDA 9.04 75% C 63% D
Management Effectiveness  
Return on Equity 17.34% 57% F 69% D+
Return on Invested Capital 12.67% 67% D+ 75% C
Return on Assets 8.56% 65% D 77% C+
Debt to Equity Ratio 9.04% 47% F 53% F
Technical Ratios  
Dividend Yield 0.55% 34% F 34% F
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.51 73% C 77% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.